Study Title
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study) (Pro00074907)
Study Number
APG2575CG301
Enrollment status
Open
Categories
B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly, Leukemia
Study Summary
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Study Coordinator(s)
- Heather, 309-243-3661 hthulean@illinoiscancercare.com